MX2023012508A - Formulaciones de anticuerpos biespecificos de alta concentracion. - Google Patents

Formulaciones de anticuerpos biespecificos de alta concentracion.

Info

Publication number
MX2023012508A
MX2023012508A MX2023012508A MX2023012508A MX2023012508A MX 2023012508 A MX2023012508 A MX 2023012508A MX 2023012508 A MX2023012508 A MX 2023012508A MX 2023012508 A MX2023012508 A MX 2023012508A MX 2023012508 A MX2023012508 A MX 2023012508A
Authority
MX
Mexico
Prior art keywords
high concentration
formulations
bispecific antibodies
methods
pharmaceutical compositions
Prior art date
Application number
MX2023012508A
Other languages
English (en)
Spanish (es)
Inventor
Roland Knoblauch
Satyen Torne
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2023012508A publication Critical patent/MX2023012508A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2023012508A 2021-04-21 2022-04-21 Formulaciones de anticuerpos biespecificos de alta concentracion. MX2023012508A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163177518P 2021-04-21 2021-04-21
US202163180690P 2021-04-28 2021-04-28
US202263309230P 2022-02-11 2022-02-11
PCT/IB2022/053733 WO2022224187A1 (en) 2021-04-21 2022-04-21 High concentration bispecific antibody formulations

Publications (1)

Publication Number Publication Date
MX2023012508A true MX2023012508A (es) 2023-12-15

Family

ID=81579656

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012508A MX2023012508A (es) 2021-04-21 2022-04-21 Formulaciones de anticuerpos biespecificos de alta concentracion.

Country Status (17)

Country Link
US (2) US20220395573A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326242A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024514344A (cg-RX-API-DMAC7.html)
KR (1) KR20230174239A (cg-RX-API-DMAC7.html)
AU (1) AU2022260814A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021549A2 (cg-RX-API-DMAC7.html)
CA (1) CA3217191A1 (cg-RX-API-DMAC7.html)
CR (1) CR20230497A (cg-RX-API-DMAC7.html)
EC (1) ECSP23080283A (cg-RX-API-DMAC7.html)
IL (1) IL307879A (cg-RX-API-DMAC7.html)
JO (1) JOP20230263A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012508A (cg-RX-API-DMAC7.html)
PE (1) PE20240805A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023552883A1 (cg-RX-API-DMAC7.html)
TW (1) TW202308689A (cg-RX-API-DMAC7.html)
UY (1) UY39734A (cg-RX-API-DMAC7.html)
WO (1) WO2022224187A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR123340A1 (es) * 2020-08-26 2022-11-23 Janssen Biotech Inc FORMULACIONES ESTABLES QUE COMPRENDEN UN ANTICUERPO BIESPECÍFICO PARA EGFR / c-MET
CN119790073A (zh) 2022-06-30 2025-04-08 詹森生物科技公司 使用抗EGFR/抗Met抗体治疗胃癌或食道癌
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
IL326946A (en) 2023-09-05 2026-05-01 Janssen Biotech Inc Methods of treating non-small cell lung cancer
WO2025067492A1 (zh) * 2023-09-28 2025-04-03 上海翰森生物医药科技有限公司 一种双特异性抗体在制备治疗癌症的药物中的用途
WO2025079020A1 (en) 2023-10-12 2025-04-17 Janssen Biotech, Inc. First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
WO2025158277A1 (en) 2024-01-22 2025-07-31 Janssen Biotech, Inc. Use of amivantamab to treat head and neck cancer
WO2025191459A1 (en) 2024-03-11 2025-09-18 Janssen Biotech, Inc. Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
WO2025227052A1 (en) * 2024-04-26 2025-10-30 Cephalon Llc Doses and formulations of anti-il-15 antibody for the treatment of immune diseases
WO2026022733A1 (en) 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026022739A1 (en) 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026042017A1 (en) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
KR100945108B1 (ko) * 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (egfr)에 대한 인간모노클로날 항체
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP1865986B1 (en) * 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
TWI395593B (zh) * 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US20110158987A1 (en) * 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
PT2560993T (pt) * 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
AR123340A1 (es) * 2020-08-26 2022-11-23 Janssen Biotech Inc FORMULACIONES ESTABLES QUE COMPRENDEN UN ANTICUERPO BIESPECÍFICO PARA EGFR / c-MET
US20230321087A1 (en) * 2020-09-14 2023-10-12 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies

Also Published As

Publication number Publication date
JOP20230263A1 (ar) 2023-10-19
AU2022260814A1 (en) 2023-12-07
BR112023021549A2 (pt) 2023-12-19
TW202308689A (zh) 2023-03-01
AU2022260814A9 (en) 2023-12-14
ECSP23080283A (es) 2023-11-30
UY39734A (es) 2022-10-31
CA3217191A1 (en) 2022-10-27
US20250195649A1 (en) 2025-06-19
KR20230174239A (ko) 2023-12-27
EP4326242A1 (en) 2024-02-28
WO2022224187A1 (en) 2022-10-27
PH12023552883A1 (en) 2024-05-20
PE20240805A1 (es) 2024-04-18
US20220395573A1 (en) 2022-12-15
JP2024514344A (ja) 2024-04-01
CR20230497A (es) 2023-11-15
IL307879A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
ECSP23080283A (es) Formulaciones de anticuerpos biespecíficos de alta concentración
ECSP23013655A (es) Formulaciones estables que comprenden un anticuerpo biespecífico para egfr/c-met
ECSP24044371A (es) Moléculas de anticuerpo y conjugados
PE20140614A1 (es) Anticuerpos anti-cd79b e inmunoconjugados
US12318364B2 (en) Isoflavonoid compositions and methods for the treatment of cancer
CL2015001356A1 (es) Anticuerpos bioespecificos egfr/c-met
MX2024005727A (es) Formulaciones estables que comprenden un anticuerpo biespecifico para bcma/cd3.
CL2026000307A1 (es) Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este.
CL2021002188A1 (es) Moléculas biespecíficas de unión al antígeno y métodos de uso.
AR110424A1 (es) Moléculas de unión a adam9 y métodos de uso de las mismas
RU2014139955A (ru) Прокаспазная комбинированная терапия при глиобластоме
RU2016144190A (ru) Стабильные белковые препараты, содержащие молярный избыток сорбитола
MX2025009913A (es) Anticuerpos anti-cd3 y metodos para su uso
AR122060A1 (es) Formulaciones de anticuerpos anti-il-33 y métodos de uso de las mismas
MX2020005490A (es) Anticuerpos de afinidad incrementada por el receptor del factor de crecimiento epidermico y sus fragmentos derivados.
MX2022008745A (es) Anticuerpos anti-nkp30 y metodos de uso.
BR112022010488A2 (pt) Formulação farmacêutica, uso da formulação farmacêutica, e, método para tratamento de um paciente
CL2025002685A1 (es) Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso.
MX2025010218A (es) Anticuerpos multiespecificos anti-cldn6 y anti-cd3 y metodos de uso
BR112023024775A2 (pt) Uso de uma composição terapêutica, e, método de estratificação de pacientes
AR132290A1 (es) Composiciones farmacéuticas que comprenden anticuerpos que se unen a cd30 y cd3
AR114444A1 (es) Método de secuenciación para terapia de células t con car
MX2026001145A (es) Cocristal de un inhibidor de idh1, proceso de preparacion del mismo, composiciones farmaceuticas del mismo, y metodos de tratamiento que implican el mismo